LAT pY171 Antibody, anti-human, REAfinity™
Synonyms: LAT1, pp36, p36-38
RECOMBINANT
Clone:
REA160 | I58-1169
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for LAT pY171 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-107-009, 130-106-948
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left peak) or stimulated with CD3/CD28 antibodies for 15 minutes on ice followed by stimulation with goat anti mouse IgG for 15 minutes on ice, and then allowed to undergo phosphorylation at 37 °C for 5 minutes. Cells were fixed and permeabilized using the Cell Signaling Buffer Set A followed by intracellular staining with Anti-LAT pY171 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. CD3+ cells were pregated for the analysis. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for LAT pY171 Antibody, anti-human, REAfinity™
Overview

Clone REA160 recognizes the human linker for activation of T cell family member 1 (LAT) antigen phosphorylated at tyrosine 171 (pY171). LAT is an integral membrane protein that was initially detected as a major PTK substrate during T cell–receptor (TCR) activation. It is also involved in low affinity immunoglobulin gamma Fc region receptor III mediated signaling in natural killer cells and high affinity immunoglobulin epsilon receptor mediated signaling in mast cells. TCR-mediated LAT phosphorylation is critical for the membrane recruitment of signaling complexes required for T cell–activation. The LAT protein contains a short extracellular domain, a transmembrane sequence, and an extended cytoplasmic domain with nine tyrosine residues conserved in the mouse and human sequences. Some of these tyrosine residues have been shown to be docking sites for mediators of TCR signaling. Tyrosine 171 is suggested to be involved in more than merely creating SH2-binding sites and may affect the native conformation, localization, stability, and/or sequential phosphorylation of LAT during TCR stimulation.

Additional information: Clone REA160 displays negligible binding to Fc receptors.

Alternative names

LAT1, pp36, p36-38

Detailed product information

Technical specifications

Clone
REA160
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
LAT pY171
Molecular mass of antigen [kDa]
28
Distribution of antigen
T cells, NK cells, mast cells
Entrez Gene ID
RRID
AB_2652594, AB_2652595, AB_2652593, AB_2652592

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for LAT pY171 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for LAT pY171 Antibody, anti-human, REAfinity™
Publications
  1. Zhang, W. et al. (1998) LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92 (1): 83-92
  2. Larghi, P. et al. (2013) VAMP7 controls T cell activation by regulating the recruitment and phosphorylation of vesicular Lat at TCR-activation sites. Nat Immunol 14 (7): 723-731
  3. Paz, P. E. et al. (2001) Mapping the Zap-70 phosphorylation sites on LAT (linker for activation of T cells) required for recruitment and activation of signalling proteins in T cells. Biochem. J. 356 (Pt 2): 461-471

You have previously chosen International as your location.
What do you want to do?